Cancer drugs may work by renovating the immune system's neighbourhood — not just by freeing its fighters

Checkpoint immunotherapy drugs take the brakes off the immune cells that attack cancer, but they do not help every patient, and nobody fully knew why. A Mayo Clinic team has now looked where immune responses actually begin: the lymph nodes, the busy meeting hubs where immune cells gather — and among the first places melanoma spreads. In a lab model, the treatment did far more than free up the fighter T cells. It shrank the tumour that had spread to the nodes, rearranged T cells, B cells and the node's own scaffolding cells, and flipped macrophages — helper cells that tumours can turn into suppressors — back toward stimulating the immune attack, while moving them further from the T cells they can hold back. The study, published in Communications Biology, is early-stage lab work, not a patient trial — but it suggests future treatments may work better if they fix the whole neighbourhood, not just the fighters.

SDG 3 · Good health and well-being — Mechanism: tech innovation